Epidemiology of rotavirus in infants and protection against symptomatic illness afforded by primary infection and vaccination

Vaccine. 1999 Feb 26;17(7-8):745-53. doi: 10.1016/s0264-410x(98)00258-8.

Abstract

This study assessed the frequency of symptomatic and asymptomatic primary and secondary infections with rotavirus in children under 24 months and determined protection against symptomatic illness afforded by rhesus and human-rhesus rotavirus reassortant vaccines. Successive cohorts of children (n 236) were followed through five winter rotavirus seasons with cultures of each reported episode of diarrheal disease and serologic determination of rotavirus exposure on paired sera bracketing the winter. An average of 46% of children experienced rotavirus infection in each season with almost all infected by two years of age. The relative risk of rotavirus associated gastroenteritis in naive children versus naturally immune children was 2.4 (1.1, 5.3). The relative risk of rotavirus associated gastroenteritis in naive children versus vaccinees was 4.1 (1.6, 10.7). In a community with predominantly serotype G1 rotavirus rhesus rotavirus-based vaccines are as protective against rotavirus gastroenteritis as prior natural infection.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Viral / biosynthesis
  • Antibodies, Viral / blood
  • Female
  • Gastroenteritis / epidemiology*
  • Gastroenteritis / immunology*
  • Gastroenteritis / prevention & control
  • Humans
  • Immunity, Innate / immunology
  • Immunoglobulin G / biosynthesis
  • Immunoglobulin G / blood
  • Infant
  • Male
  • Prospective Studies
  • Rotavirus / immunology
  • Rotavirus Infections / epidemiology*
  • Rotavirus Infections / immunology*
  • Rotavirus Infections / prevention & control
  • Viral Vaccines / immunology*
  • Viral Vaccines / therapeutic use

Substances

  • Antibodies, Viral
  • Immunoglobulin G
  • Viral Vaccines